Search for: "LUPIN LTD."
Results 41 - 60
of 131
Sorted by Relevance
|
Sort by Date
18 Jan 2009, 7:28 pm
Lupin Ltd. et al.1:09-cv-00083; filed January 14, 2009 in the District Court of MarylandInfringement of U.S. [read post]
21 Nov 2012, 11:32 am
Lupin Ltd., C.A. [read post]
3 Aug 2012, 9:51 am
Lupin Ltd. [read post]
17 May 2009, 9:19 pm
Lupin Ltd. et al. 1:09-cv-01258; filed May 14, 2009 in the District Court of Maryland Infringement of U.S. [read post]
8 Mar 2009, 5:59 pm
Lupin Ltd. et al. 1:09-cv-00147; filed March 5, 2009 in the District Court of Delaware Infringement of U.S. [read post]
14 Jan 2024, 9:29 pm
Lupin Ltd. [read post]
2 Jan 2024, 8:45 pm
Lupin Ltd. [read post]
18 Jan 2024, 9:16 am
Additionally, Lupin Ltd. and Lupin Pharmaceuticals, Inc. [read post]
25 Jan 2024, 8:25 pm
Lupin Ltd. [read post]
30 Sep 2013, 8:12 am
District Court for the District of Delaware against Apotex Corp.; Hetero USA Inc.; Lupin Ltd.; Mylan Pharmaceuticals, Inc.; Par Pharmaceuticals, Inc.; Ranbaxy Laboratories Ltd.; and related companies and subsidiaries. [read post]
17 Oct 2007, 10:00 pm
I have just found out from the Generic Pharmaceuticals and IP blog that Teva has now sued 16 companies in relation to its Carvedilol process patents.The 16 defendants are: Zentiva; Mylan; Taro Pharmaceuticals; Lupin; Moehs Iberica; Urquima; Orchid; Wanbury;Z hejiang Huahai; USV Ltd.; Cadila; Ranbaxy; Dr. [read post]
11 Sep 2007, 10:31 am
Lupin Ltd. [read post]
17 Sep 2007, 2:00 pm
Lupin, Ltd. (06-1530). [read post]
1 Nov 2010, 11:41 am
Lupin, Ltd. et al., 2-10-cv-00080 (NJD October 27, 2010, Order) (Hochberg, J.). [read post]
21 Apr 2013, 1:42 am
This year Dr Rowe has again appeared in court on behalf of generic manufacturers – Generic Health Pty Ltd and Lupin Australia Pty Ltd – where it seems his past has come back to haunt him. [read post]
20 Mar 2015, 11:58 am
Lupin Ltd., 684 F.3d 1253, 1260 (Fed. [read post]
12 Sep 2007, 4:59 am
Lupin, LTD., et al. [read post]
7 Jan 2024, 9:59 pm
Lupin Ltd. [read post]
13 Feb 2008, 6:19 pm
Lupin Ltd. allegedly submitted, through its agent Lupin Pharma, an Abbreviated New Drug Application No. 90-051 to the FDA for approval to market generic Namenda®. [read post]